NetScientific PLC (LON:NSCI) has announced that its portfolio company Vortex Biosciences has appointed Bob Englert as new chief executive officer.
The healthcare IP commercialisation group said Bob Englert, who is currently chief technology officer, takes up the position with immediate effect, replacing Gene Walther, who has resigned to pursue other interests.
The company said Bob Englert, who has been chief technology officer of Vortex since 2016, has over 25 years of global experience in medical devices and life sciences, with a particular focus on IVD, Point of Care, digital health solutions.
Vortex has also appointed Steve Crouse, who has been chief commercial officer since March 2016, to the position of chief operating officer. He will work closely with Bob Englert and the board to drive R&D and commercialisation strategies.
François R. Martelet, CEO of NetScientific and chairman of Vortex Biosciences, said: “Vortex is approaching a critical commercialisation phase with its unique CTC isolation technology, and Bob is in a unique position to drive this forward.”
He added: “With expertise gained from his role as chief technology officer and underpinned by years of industry experience, particularly in the diagnostics field, we believe he is the right person to take Vortex through the next phase of its growth.”